|Generate QR code
Open Access
Subscription Access
Derivative Spectrophotometric Methods for Determination of Idelalisib in Bulk and in Formulation
Abstract
Idelalisib is a phosphatidylinositol 3-kinase delta inhibitor approved by the FDA and the EMA for the treatment of lympholytic lymphoma, B cell non-Hodgkin lymphoma, and lymphocytic lymphoma. The present report describes the validation of a simple, rapid, sensitive, and cost-effective zero-order and first-order derivative spectrophotometric method for the estimation of idelalisib in bulk and in its marketed formulation. Preliminary spectrophotometric analysis of the drug was carried out in methanol and a total of 12 parametric variations were considered. Three selected method variants employing peak-zero and peak-peak techniques were assessed for their stability indicating potential in stress degraded solutions of the drug. The developed method was validated with respect to linearity, accuracy, precision, and robustness. Excellent linearity was observed within the concentration range 1.0–60.0 μg/mL with a correlation coefficient of 0.9997. The limits of assay detection values were found for the range 0.42–3.11 μg/mL, and quantitation limits ranged from 1.29 to 9.42 μg/mL for the proposed method variants. The proposed method was used to quantify the drug in its marketed tablet formulation, and good recoveries ranging from 95.98 to 98.81% were obtained.
Supporting agencies: This work was supported by the University Grants Commission (UGC), New Delhi, India (Grant No. 36/N/296).
About the Authors
M. Mahesh
University Institute of Pharmaceutical Sciences
India
India
UGC Center of Advanced Study,
Panjab University, Chandigarh
A. Bali
University Institute of Pharmaceutical Sciences
India
India
UGC Center of Advanced Study,
Panjab University, Chandigarh
T. Gupta
University Institute of Pharmaceutical Sciences
India
India
UGC Center of Advanced Study,
Panjab University, Chandigarh
S. Shekhar
University Institute of Pharmaceutical Sciences
India
India
UGC Center of Advanced Study,
Panjab University, Chandigarh
References
1. L. A. Raedler, Am. Health Drug Benefits., 8, 157–162 (2015).
2. A. Davies, Expert Rev. Hematol., 8, No. 5, 581–593 (2015).
3. A. Markham, Drugs, 74, No. 14, 1701–1707 (2014).
4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20654 5lBl.pdf (last time accessed: January 25, 2023).
5. Zydelig®. (Idelalisib). Highlights of prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206545lbl.pdf.Accessedon15November2020 (last time accessed: January 25, 2023).
6. ZYDELIG Product Information v4.0 (2017) https://www.tga.gov.au/sites/default/files/auspar-idelalisib171019-pi.pdf (last time accessed: February 21, 2022).
7. R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, I. Flinn, P. Ghia, H. Eradat, T. Ervin, N. Lamanna, B. Coiffier, A. R. Pettitt, S. Ma, S. Stilgenbauer, P. Cramer, M. Aiello, D. M. Jhonson, L. L. Miller, D. Li, T. M. Jahn, R. D. Dansey, M. Hallek, S. M. O’Brien, N. Engl. J. Med., 370, No. 11, 997–1007 (2014).
8. H. K. Tripathy, N. V. S. Manju, S. Dittakavi, A. Zakkula, R. Mullangi, Drug Res., 71, No. 1, 36–42 (2021).
9. H. H. Huynh, C. Roessle, H. Sauvageon, A. Ple, I. Madelaine, C. Thieblemont, S. Mourah, L. Goldwit, Ther. Drug Monit., 40, 237–244 (2018).
10. A. Suneetha, D. Sharmila, Int. J. Pharm. Sci. Res., 7, No. 12, 4998(1–5) (2016).
11. S. Veeraraghavan, S. Thappali, S. Viswanadha, S. Nalla, S. Chennupati, M. Golla, S. Vakkalanka, M. Rangaswamy, J. Chromatogr., 949-950, 63–69 (2014).
12. C. Wang, F. Jia, Y. Zhang, Biomed. Chromatogr., 33, e4511 (2019).
13. B. B. Gabani, S. Dittakavi, P. K. Kurakula, U. Todmal, M. Zainuddin, R. K. Trivedi, R. Mullangi, Anal. Chem., 11, No. 2, 140–152 (2021).
14. V. Bommuluri, S. Vajjha, C. S. Rumalla, S. Kadari, R. Doddipalla, M. Kaliyaperumal, R. B. Korupolu, V. Choppela, Sep. Sci. Plus, 3, 330 (1—9) (2020).
15. ICH, Validation of analytical procedures: text and methodology Q2 (R1), in International conference on harmonization, Geneva, Switzerland 11, 1–13 (2005).
Review
For citations:
Mahesh M., Bali A., Gupta T., Shekhar S. Derivative Spectrophotometric Methods for Determination of Idelalisib in Bulk and in Formulation. Zhurnal Prikladnoii Spektroskopii. 2024;91(3):469.
Views: 42
Email this article 